Chapter title |
SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
|
---|---|
Chapter number | 2 |
Book title |
Ovarian Cancer
|
Published in |
Advances in experimental medicine and biology, January 2008
|
DOI | 10.1007/978-0-387-68969-2_2 |
Pubmed ID | |
Book ISBNs |
978-0-387-68966-1, 978-0-387-68969-2
|
Authors |
Ingegerd Hellstrom, Karl Erik Hellstrom, Hellstrom, Ingegerd, Hellstrom, Karl Erik |
Abstract |
Assays measuring SMRP (mesothelin) and HE4 (a secreted protease) in serum and other body fluids (including urine for SMRP) are likely to be clinically useful for patients with ovarian cancer, as data indicate that they complement CA125 for diagnosis and monitoring of patients. Both markers have temporal stability, as does CA125, which may be utilized to facilitate earlier diagnosis by performing longitudinal studies on high risk subjects. Preliminary data show autoantibodies to native mesothelin in some patients with ovarian carcinoma and in some healthy women. We are presently studying their relationship to the patients' clinical state to learn whether measurements of antibody levels provide information that can aid diagnosis and monitoring of treated patients. Prospective studies are needed to establish the clinical relevance of our findings. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 4% |
Netherlands | 1 | 4% |
Unknown | 25 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 19% |
Student > Master | 4 | 15% |
Student > Ph. D. Student | 3 | 11% |
Student > Doctoral Student | 2 | 7% |
Other | 2 | 7% |
Other | 5 | 19% |
Unknown | 6 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 37% |
Agricultural and Biological Sciences | 4 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Chemistry | 1 | 4% |
Other | 1 | 4% |
Unknown | 9 | 33% |